Carregant...
Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension
STUDY OBJECTIVES: Esmirtazapine (1.5–4.5 mg) has demonstrated short-term sleep-promoting effects in nonelderly outpatients with chronic insomnia. This phase 3, randomized, double-blind study (NCT00631657) and its open-label extension (NCT00750919) investigated efficacy and safety of long-term esmirt...
Guardat en:
| Publicat a: | J Clin Sleep Med |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Academy of Sleep Medicine
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970588/ https://ncbi.nlm.nih.gov/pubmed/32351205 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5664/jcsm.8526 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|